Skip to main content
S

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,111 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于收到终止上市事先告知书的公告
Regulatory Filings
2026-05-07 Chinese
关于公司股票可能被终止上市的第六次风险提示公告
Regulatory Filings Classification · 72% confidence The document is a Chinese stock exchange announcement titled “第六次风险提示公告” regarding the company’s potential stock delisting risk under Shenzhen Stock Exchange listing rules. It is a periodic risk warning announcement (the sixth such notice) rather than the actual delisting decision or a financial report. It does not fit specialized categories such as 10-K, IR, ER, DLST (actual delisting), or others. Therefore, it falls into the general Regulatory Filings category (RNS).
2026-04-17 Chinese
关于公司向关联方借款暨关联交易的公告
Capital/Financing Update Classification · 90% confidence The document is a formal stock exchange announcement by *ST赛隆 (Securities code 002898) detailing the terms and board approvals for a RMB1 billion related-party loan. It is not a dividend, AGM material, share issue, director deal, or legal proceeding; rather it describes new financing via a related-party loan, fitting the Capital/Financing Update category.
2026-04-14 Chinese
第四届董事会独立董事2026年第一次专门会议的审查意见
Governance Information Classification · 85% confidence The document is the formal opinions of the company’s independent directors at a special board meeting reviewing a related‐party loan transaction. It is not an earnings release, annual or interim financial report, nor a proxy, dividend, M&A or capital notice. Instead, it is a governance‐related board‐level document outlining internal review procedures under listing rules. Therefore, it falls under Governance Information (CGR).
2026-04-14 Chinese
第四届董事会第二十四次会议决议公告
Board/Management Information Classification · 85% confidence The document is an announcement of the Board of Directors’ meeting resolution: date of meeting, attendance, items considered, voting results, and references to the board’s approval of a related-party loan. This is not a shareholder vote (so not DVA), nor a change in board membership per se; however it is a board/management information document detailing board decisions. Therefore, it falls under Board/Management Information (MANG).
2026-04-14 Chinese
关于继续公开挂牌转让全资子公司股权的进展公告
Regulatory Filings
2026-03-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.